Farmington, May 11, 2023 (GLOBE NEWSWIRE) -- The Global Acne Medicine market size was valued at USD 6.1 billion in 2022 and is projected to reach USD 10.8 billion by 2030, growing at a CAGR of 7.40% from 2023 to 2030. During puberty, an increase in androgen (estrogen in females) increases the oil glands under the epidermis, causing the onset of this condition. This results in excessive sebum production, which deteriorates cell walls and pores, allowing microbes to invade the skin. Although some studies indicate that genetics can increase the risk of developing acne, other factors such as emotional stress, menstruation, hot weather and humidity, and bright jewelry can provoke acne outbreaks.
Request Sample Copy of Report “Acne Medicine Market Size, Share & Trends Estimation Report By Type (Prescription Medicine, Over the counter (OTC) Medicine), By Route of Administration (Topical, Oral, Injectable), By Application (Inflammatory Acne, Non-inflammatory Acne), By Region, And Segment Forecasts, 2023 – 2030.”, published by Contrive Datum Insights.
Segmentation Overview:
Deployment Outlook:
Based on Type, the market is bifurcated into Inflammatory Acne, Cystic Acne, and Post-Surgical/Wound Acne. The inflammatory acne segment held the largest market share. The factors can be attributed to the permanent solution for skin problems, reducing the probability of future problems, and the availability of well-trained dermatologists.
Organization Outlook:
Based on Treatment Modality, the market is bifurcated into Oral and Topical. The topical formulations hold maximum market share. The factors can be credited for the rise in the adoption of skincare products and the demand for minimally invasive cosmetic treatment procedures.
Regional Analysis:
North America holds the largest market share for acne treatments and is anticipated to maintain its dominance throughout the forecast period. This is due to factors such as the metropolitan population's unhealthy lifestyle and diet, which contribute to the prevalence of acne in this region. According to the American Academy of Dermatology (AAD) of 2022, an estimated 50 million individuals in the United States suffered from acne in 2021. In addition, Bausch Health Companies Inc., Mylan N.V., Pfizer Inc., and Johnson & Johnson will contribute to the region's market expansion.
Buy this Premium Research Report@
https://www.contrivedatuminsights.com/buy/8071
Scope of Report:
| Report Attributes | Details |
| Growth Rate | CAGR of 7.4% from 2023 to 2030. |
| Revenue Forecast by 2030 | USD 10.8 Billion |
| By Type |
|
| By Application |
|
| By Route of Administration |
|
| By Industries |
|
| By Companies |
|
| Regions and Countries Covered |
|
| Base Year | 2022 |
| Historical Year | 2017 to 2022 |
| Forecast Year | 2023 to 2030 |
Market Dynamics:
Drivers and Restraints:
The expansion of the acne treatment pipeline is anticipated to drive market growth over the forecast period. For instance, in April 2021, Bausch Health Companies Inc., a global healthcare company, and Ortho Dermatologics, one of the leading prescription dermatological health care companies, announced statistically significant results at the highest level of their second pivotal Phase 3 clinical trial evaluating IDP-126. A topical combination retinoid, antibacterial, and antibiotic for the treatment of acne vulgaris in patients aged 9 and up. If authorized, the IDP-126 will be the first product to employ this triple combination.
High side effects associated with acne treatments and the increasing use of alternative treatments are the primary factors inhibiting the growth of the global acne treatment market. The side effects of acne medications depend on the treatment's type and intensity. For instance, the most common adverse effects of topical acne treatments are skin dehydration and irritation. Oral and topical medications may have distinct effects but comparable adverse effects. Serious side effects of acne medications include rash or hives, swelling of the face, lips, or tongue, severe burning or swelling of the treated area, constriction of the pharynx, shortness of breath, or difficulty breathing.
Key Segments Covered:
Top Market Players:
- Allergan
- Nestle (Galderma)
- Johnson & Johnson
- Mayne Pharma
- Mylan
- Pfizer
- Vyome Biosciences
- Foamix Pharmaceuticals
- Valeant Pharmaceuticals
- Bio Pharm
- Others.
By Type
- Prescription Medicine
- Over-the-counter (OTC) Medicine
- Other
By Application
- Inflammatory Acne
- Non-inflammatory Acne
- Other
By Route of Administration:
- Topical
- Oral
- Injectable
- Other
By Industries
- Government
- Healthcare
- Retail
- Manufacturing
- Others
- BFSI
- IT and telecom
Regions and Countries Covered
- North America: (US, Canada, Mexico, Rest of North America)
- Europe: (Germany, France, Italy, Spain, UK, Nordic Countries, Benelux Union, Rest of Europe)
- Asia-Pacific: (Japan, China, India, Australia, South Korea, Southeast Asia, Rest of Asia-Pacific)
- The Middle East & Africa: (Saudi Arabia, UAE, Egypt, South Africa, Rest of the Middle East & Africa)
- Latin America: (Brazil, Argentina, Rest of Latin America)
- Rest Of the World
Check out more related studies published by Contrive Datum Insights:
- Acne Treatment Market - The Global acne treatment market size was valued at USD 4.7 billion in 2022 and is expected to grow USD 16.9 Billion with a growing compound annual growth rate (CAGR) of 4.2% from 2022 to 2030.
- Dermatophytic Onychomycosis Treatment Market -The Global Dermatophytic Onychomycosis Treatment Market Size Was Valued At USD 3.74 Billion In 2022 And Is Projected To Reach USD 6.63 Billion By 2030, Exhibiting A CAGR Of 7.4% During The Forecast Period.
- Oral Solid Dosage Pharmaceutical Formulation Market - The Global Oral Solid Dosage Pharmaceutical Formulation Market Was Valued At USD 23.4 Billion In 2022 And Is Expected To Climb At A CAGR Of 5.9% To A Valuation Of USD 43.6 Billion By The End Of 2030.
Customization of the Report: The report can be customized as per client needs or requirements.For any queries, you can contact us on anna@contrivedatuminsights.com or +1 215-297-4078. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.
About Us:
Contrive Datum Insights (CDI) is a global delivery partner of market intelligence and consulting services to officials at various sectors such as investment, information technology, telecommunication, consumer technology, and manufacturing markets. CDI assists investment communities, business executives, and IT professionals to undertake statistics-based accurate decisions on technology purchases and advance strong growth tactics to sustain market competitiveness. Comprising of a team size of more than 100 analysts and cumulative market experience of more than 200 years, Contrive Datum Insights guarantees the delivery of industry knowledge combined with global and country-level expertise.
Social: Facebook / LinkedIn / Twitter
Contact Us:
Anna B. | Head Of Sales
Contrive Datum Insights
Phone: +91 9834816757 | +1 2152974078
Email: anna@contrivedatuminsights.com
Website:
https://www.contrivedatuminsights.com
Contrive Datum Insights Press Releases
Latest Contrive Datum Insights Latest Reports
